Notably, clinical trials using cytokine-induced memory-like (CIML) NK cells in AML have shown promising results.49 These NK cells have high expression of NKG2A, downregulated KIRs and exhibit enhanced functional responses against leukemic cells. This evidence concerns the gene KLRC1 and acute myeloid leukemia.